Illinois Selects Tepnel CF Test for Newborn Screening | GenomeWeb
NEW YORK (GenomeWeb News) – Manchester, UK-based Tepnel Life Sciences today said that the Illinois Department of Public Health has selected its Elucigene CF-US test for two-stage testing of cystic fibrosis under a newly mandated screening program for all newborns in the state.
 
Tepnel’s test is designed for use on high-throughput capillary sequencers and detects 44 mutations in the cystic fibrosis transmembrane conductance regulator gene and their wild-type counterparts.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.